The Pharmacy Compounding Advisory Committee voted on Thursday and Friday to recommend adding six peptides to an approved compounding list, a step that could widen a regulated path for specialty pharmacies. The non-binding vote still needs sign off from the FDA, and the panel rejected emideltide.
Thursday and Friday vote
The six peptides are BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. If the FDA accepts the recommendation, specially licensed compounding pharmacies could use them in customized medications under a narrow regulated path, but the decision would not turn them into supplements on a store shelf or make them FDA-approved medicines.
That distinction matters because compounds already sold online as unregulated research chemicals would remain outside ordinary retail channels. The committee action would instead give specialty pharmacies a legal framework for making certain preparations to order, while leaving the FDA’s broader safety and effectiveness judgments unchanged.
Robert F. Kennedy Jr., who oversees the FDA as HHS secretary, has expressed support for peptides. His backing for the 8-6 vote adds political weight to a recommendation that remains advisory until the FDA acts.
Dr. Haleem Mohammed
Dr. Haleem Mohammed said during Thursday’s committee discussion, "As a physician, I have to make sure that I'm keeping patients as safe as possible" and added, "So, when I look at something like saying no to this and pushing it to the gray market, am I doing greater harm? That's what I lose sleep at night over." His remarks reflected the tradeoff members weighed while deciding whether to keep the compounds off or move them into a narrower regulated channel.
FDA staff scientists opposed adding every peptide to the list. On emideltide, the FDA said it was proposed as an under-the-skin injection to treat narcolepsy and opioid withdrawal, while the clinical studies used an intravenous route. The evidence base for that peptide consisted of a single patient case report for narcolepsy and two small, uncontrolled studies for opioid withdrawal.
Emideltide evidence
The committee rejected emideltide after hearing that record. Dr. Adriane Fugh-Berman, a professor of pharmacology and physiology at Georgetown University, told the panel, "Would the government endorse manufacturing heroin because it's cleaner than what is sold on the street?" She also said, "Just because a market is large doesn't mean that a product should be legalized. It means that a product should be studied."
Six of the eight recently appointed members run clinics that offer peptides, a detail that framed the vote but did not change the final count. The FDA now has to decide whether to sign off on the committee’s recommendation for the six peptides, while emideltide stays out of the approved compounding list.
